A Multi-Center, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 [AL101] in Participants with Early Alzheimer’s Disease.
This research is an extension of an earlier study, focusing on a new medicine called GSK4527226 (or AL101) for people living with early Alzheimer’s disease. The main goal is to understand how safe the medicine is over a longer time and whether it helps improve or maintain memory, thinking skills, and the ability to do everyday tasks. This is an "open-label" study, meaning everyone involved will know they are receiving the study medicine. Researchers will carefully watch for any side effects and see how the medicine might affect the disease progression. It's designed to gather more long-term information on this potential new treatment.
At a glance
What is this study about?
This research is a continuation study, following on from an earlier trial, to learn more about a new medicine called GSK4527226, also known as AL101. It's specifically for people who are in the early stages of Alzheimer’s disease. The main focus is to understand how safe the medicine is when taken for a longer period and to see if it helps with the symptoms of Alzheimer's, like memory problems and difficulties with daily activities.
The study is called an "open-label extension." This means that everyone taking part will know they are receiving the study medicine, rather than a placebo (a dummy drug). This approach helps researchers gather more information on the long-term effects of the medicine after the initial treatment period.
The researchers will be very carefully monitoring participants for any side effects, particularly focusing on specific types of side effects that have been seen with similar medicines. They will also be looking to see if the medicine helps people with their memory, thinking, and their ability to manage daily life tasks. This kind of study is important because it helps scientists understand if new medicines could be a helpful option for people with Alzheimer's disease in the future.
Key takeaways
- This study explores a new medicine, GSK4527226 (AL101), for early Alzheimer's disease.
- It's an extension for people who were already in an earlier study for this medicine.
- The main goals are to check the medicine’s long-term safety and its effect on memory and daily life.
- Participants will receive the study medicine, and regular health checks will be part of the process.
- Taking part helps advance research for Alzheimer's treatments.
Who may be eligible?
To be able to join this study, people generally need to be adults, aged 18 years or older, with no upper age limit.
Crucially, this study is specifically for people who have already taken part in an earlier study for this same medicine, GSK4527226 (AL101). It is designed to extend the research for those who have already completed the initial trial.
Key health information will be checked by the study team to make sure it's safe for you to take part. This includes reviewing your medical history and current health status.
- Are you 18 years old or older?
- Have you already participated in the earlier study for GSK4527226 (AL101)?
- Are you in the early stages of Alzheimer's disease?
- Are you willing to attend regular clinic visits?
- Are you comfortable with the possibility of experiencing side effects?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
Taking part in this study would involve regular visits to the study clinic. During these visits, the study team would give you the medicine, GSK4527226 (AL101), and you would have various health checks. These checks might include blood tests, physical examinations, and assessments of your memory and thinking skills through simple tests and questionnaires.
The purpose of these regular assessments is for the researchers to monitor your health, look for any side effects, and see how the medicine might be affecting your Alzheimer's disease over time. The total duration of your participation would depend on the study design, but generally, extension studies like this one can last for several months or even longer.
Potential risks and benefits
Locations (8)
- —Sweden
- —Norway
- —Italy
- —France
- —Spain
- —Finland
- —Netherlands
- —Germany
Common questions
What is Alzheimer's disease?
Alzheimer's disease is a brain condition that slowly gets worse over time, affecting memory, thinking, and behaviour.
Is GSK4527226 a new medicine?
Yes, GSK4527226 (AL101) is a new investigational medicine that scientists are studying to see if it can help people with Alzheimer's disease.
What does 'long-term safety' mean?
It means the researchers will be watching very closely for any side effects or health changes over a longer period while people take the medicine.
Will I know if I'm getting the actual medicine?
Yes, this is an 'open-label' study, which means everyone taking part will receive the study medicine, GSK4527226 (AL101).
Why is this study important?
This study is important because it helps scientists gather more information about new potential treatments for Alzheimer's disease, particularly how safe and effective they are over a longer period.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.